It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.

ABSTRACT:

Abstract

Approximately half of patients with chronic lymphocytic leukemia (CLL) will never require treatment; nonetheless, they are recommended life-long specialized follow-up (sFU). To prioritize health care resources, local hospital management implemented ending sFU in asymptomatic patients with CLL International Prognostic Index (CLL-IPI) and CLL without need of treatment (CLL-WONT) low-to-intermediate risk, who were covered by universal health care. To evaluate the feasibility and safety of ending sFU, we investigated 3-year clinical outcomes among 112 patients selected by clinical assessment to end sFU as compared with 88 patients selected to continue sFU. Patients who ended sFU were older, but otherwise lower risk compared with patients continuing sFU. Overall survival (OS) w

SUBMITTER: Brieghel C 

PROVIDER: S-EPMC11445221 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature